Adjunctive antipsychotics for MDD differ in efficacy and acceptability
The Brown University Psychopharmacology Update · 2026-09 · 37 (9) · 1-6
DOI: 10.1002/pu.31485 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 03.08.2026.
Abstract (Originalsprache)
A systematic review and network meta‐analysis has found considerable differences in efficacy and acceptability among atypical antipsychotics used as adjunctive treatment for major depressive disorder (MDD). Lumateperone had the greatest effect size for efficacy, and aripiprazole had the highest level of acceptability. Results of the systematic review and meta‐analysis were published online May 6, 2026 in JAMA Psychiatry .
Zitieren
APA
(2026). Adjunctive antipsychotics for MDD differ in efficacy and acceptability. The Brown University Psychopharmacology Update, 37(9), 1-6. https://doi.org/10.1002/pu.31485
Vancouver
Adjunctive antipsychotics for MDD differ in efficacy and acceptability. The Brown University Psychopharmacology Update. 2026;37(9):1-6. doi:10.1002/pu.31485
BibTeX
@article{euvimed2026,
title = {Adjunctive antipsychotics for MDD differ in efficacy and acceptability},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {9},
pages = {1--6},
doi = {10.1002/pu.31485}
}
EUVIMED